The Serum Institute of India (SII), located in Pune, has introduced Cervavac, the country’s first quadrivalent Human Papillomavirus (qHPV) vaccine, designed for the prevention of cervical cancer. Developed and manufactured by SII, the vaccine has now been made available in the private market. Cervical cancer is a major concern in India, with the country accounting for 27% of global cases. The new vaccine, which targets four strains of HPV, is expected to significantly reduce the incidence of cervical cancer and related fatalities in India. Alongside private distribution, the Indian government is also planning to facilitate the widespread dissemination of the vaccine. The move aims to address the disparities in access to healthcare and ensure that the vaccine reaches a larger population, particularly in rural areas. With this development, India is taking a significant step forward in the fight against cervical cancer and prioritizing women’s health.
Today: December 9, 2023